Norwood Investment Partners Opens New $4.3 Million Cellebrite Position

Norwood initiated Cellebrite position and now holds 230,671 shares, worth an estimated $4.27 million. The stake represents 3.68% of 13F reportable assets under management.

The Motley Fool • Dec 9, 2025

Cellebrite: Solid Setup Going Into Next Year

Cellebrite remains a "Buy" as federal demand rebounds and platform adoption accelerates, supporting a strong long-term growth outlook. The federal segment returned to year-over-year growth in Q3, removing the primary bear case and confirming demand was delayed, not lost. Inseyets migration and rapid cloud/SaaS ARR growth—Guardian cloud ARR up >100% for five quarters—position CLBT for outsized ARR acceleration into 2026.

Seeking Alpha • Dec 5, 2025

10 AI Stocks Worth Buying Right Now

Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.

The Motley Fool • Dec 4, 2025

Cellebrite Completes Acquisition of Corellium, Extending the Industry's Most Advanced AI-Powered Digital Investigation Platform

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced it has substantially expanded its capabilities through the acquisition of Corellium, a leader in Arm-based virtualization software.

GlobeNewsWire • Dec 2, 2025

Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript

Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Cellebrite DI: Strong Q3, But Valuation And Technical Issues Could Weigh On The Stock (Rating Downgrade)

Cellebrite DI remains a long-term growth story, despite recent volatility and a modest stock decline since November 2024. CLBT's Q3 2025 earnings beat analyst expectations, with revenue up 18% year-over-year to $126 million and EPS of $0.14. Valuation and technical concerns persist, which could lead to further selling or an underperformance for the stock.

Seeking Alpha • Nov 22, 2025

Should Investors Buy Shares of Cellebrite Alongside Portolan Capital as They Double Down on the Stock?

Portolan Capital increased its Cellebrite position by 1,407,818 shares, worth an estimated $28.65 million. The transaction equates to approximately 1.20% of 13F reportable assets under management (AUM).

The Motley Fool • Nov 19, 2025

Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter

Delaware-based Ashford Capital Management increased its position Cellebrite by 434,615 shares during the third quarter, adding an estimated $11.3 million in value to its stake. At quarter-end, Ashford reported holding 1.7 million shares of Cellebrite valued at $31.5 million as of September 30.

The Motley Fool • Nov 17, 2025

Why Cellebrite Stock Is Skyrocketing Today

Cellebrite topped Wall Street's sales and earnings expectations for the third quarter. The company also raised its full-year guidance.

The Motley Fool • Nov 13, 2025

Cellebrite DI Ltd. (CLBT) Q3 2025 Earnings Call Transcript

Cellebrite DI Ltd. ( CLBT ) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Company Participants Andrew Kramer - Vice President of Investor Relations Thomas Hogan - CEO & Director David Barter - Chief Financial Officer Marcus Jewell - Global Chief Revenue Officer Conference Call Participants Jeff Van Rhee - Craig-Hallum Capital Group LLC, Research Division Brian Essex - JPMorgan Chase & Co, Research Division Tomer Zilberman - BofA Securities, Research Division Louie Dipalma - William Blair & Company L.L.C.

Seeking Alpha • Nov 13, 2025